Latest News

 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

LONDON–(BUSINESS WIRE)–Vertex announced reimbursement of SYMDEKO for eligible patients ages 12 and older, and ORKAMBI for children ages 2 to 5 in Australia.

Source link

Related posts

Study: Environment changes can impact stability landscape of the gut microbial community


Prioritisation of Old Apartment Buildings for Energy-efficient Refurbishment Based on the Effects of Building Features on Energy Consumption in South Korea


Florida can require licenses for dietary advice, court rules


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World